



Esbriet

Scroll for select Important Safety Information

About Esbriet

Esbriet® (pirarubicin) is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF).

Select Important Safety Information



December 22, 2016

834 people on this site
powered by Curebit

Other search tools:

Drugs

Diseases

News

Media Pack

Contact Us

Newsletters



Dixie announces new hemp-based Cannabidiol products without THC

Published on May 7, 2012 at 7:44 AM 12 Comments

[Like 1](#) [Share](#) [Share](#) [Stumble](#) [G+](#) [Tweet](#)

Dixie Elixirs and Edibles, Colorado's premier Tetrahydrocannabinol or THC-infused products company, today announced a new line of products which will break entirely new ground for the company in the category of non-THC-infused product development. Following closely on the heels of its acquisition by cannabis and hemp industry innovators Medical Marijuana, Inc. (OTC: MJNA), today's announcement consists of three new hemp-based Cannabidiol (CBD) products that contain no THC:

"From the day that we created our first medicated elixirs, we have known that as an industry we have only just begun to tap the very deep health and healing properties of cannabis"

- Dixie DewDrops: a sublingual glycerin-based tincture designed for pain relief
- Dixie Botanicals: a topical pain relief salve and massage oil
- Dixie Scripts: a pharmaceutical-grade CBD capsule in two varieties, one for daytime focus/mental energy and the other a night time sleep aid

The Food and Drug Administration (FDA) currently considers hemp-based cannabinoids, including CBD, to be "food based" and therefore legal without a medical marijuana license. Amongst the many potential uses for CBD-based products that are currently under evaluation, CBD's have been shown to relieve convulsion, inflammation, anxiety, and nausea. Based on medical potential and the federally legal status of hemp-based CBD products, Dixie and Medical Marijuana, Inc. estimate the market in the U.S. to be well over \$5 billion. These three new products are the first of many that the companies intend to bring to the market in the coming year.

Dixie will initially offer the new products exclusively to their existing customer base which consists of over 400 dispensaries in the state of Colorado. This consumer base represents in excess of 70 percent of the addressable medical marijuana market in Colorado and over nine percent of the U.S. medical cannabis market. Within 90 days the Company intends to launch a mail order campaign and online e-commerce platform that will allow individuals throughout the U.S. to purchase these products since they contain no THC. The U.S. availability will be followed closely by distribution in international markets including Europe via several key product distribution relationships that are currently under negotiation.

"From the day that we created our first medicated elixirs, we have known that as an industry we have only just begun to tap the very deep health and healing properties of cannabis," said Tripp Keber, President and CEO of Dixie Elixirs and Red Dice Holdings, LLC. "These three new products open up a world of potential for Dixie and Medical Marijuana, Inc. to bring healthy alternatives to millions of patients who might otherwise never experience the tremendous benefits of cannabinoids. This is truly an exciting development for Dixie and we look forward to bringing Dixie Scripts, Dixie DewDrops, and Dixie Botanicals to patients around the country and around the world who are looking for a healthful alternative to mass-produced, man-made pharmaceutical products."

Source:
Dixie Elixirs and Edibles

Be the first to rate this post

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Tags: Anxiety, Cannabis, Nausea, Pain, Sleep

GAZYVA

WITH GAZYVA,
WHAT ARE
YOUR
POSSIBILITIES?

G

Click to reveal

↓ Scroll to reveal important safety information, including drug and treatment interactions.

▲ IMPORTANT SAFETY INFORMATION
BASED WARNINGS:
 HEPATITIS B VIRUS
 REACTIVATION AND
 PROGRESSIVE
 MULTIFOCAL
 LEUKOENCEPHALOPATHY
 - Hepatitis B Virus (HBV)
 reactivation, in some
 cases resulting in
 fulminant hepatitis,
 hepatic failure, and
 death, can occur in
 patients receiving GAZYVA.
 directed cytolytic

Advertisement